MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Assertio Holdings Inc

Closed

0.68

Overview

Share price change

24h

Current

Min

0.66

Max

0.69

Key metrics

By Trading Economics

Income

-3.1M

-14M

Sales

-5.7M

26M

Profit margin

-51.121

Employees

58

EBITDA

-10M

-13M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+305.8% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

3.9M

63M

Previous open

0.68

Previous close

0.68

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Assertio Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lip 2025, 15:46 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lip 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lip 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 20:26 UTC

Earnings

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lip 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lip 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lip 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lip 2025, 17:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 lip 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 lip 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lip 2025, 16:14 UTC

Acquisitions, Mergers, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lip 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lip 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lip 2025, 15:31 UTC

Major Market Movers

BitMine Shares Fall After Closing of $250M Private Placement

9 lip 2025, 15:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lip 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lip 2025, 14:36 UTC

Acquisitions, Mergers, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lip 2025, 14:31 UTC

Acquisitions, Mergers, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lip 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 lip 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer Comparison

Price change

Assertio Holdings Inc Forecast

Price Target

By TipRanks

305.8% upside

12 Months Forecast

Average 2.8 USD  305.8%

High 3.5 USD

Low 1.5 USD

Based on 5 Wall Street analysts offering 12 month price targets forAssertio Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.618 / 0.649Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Assertio Holdings Inc

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.